- Home
- BIIB vs HAL Comparison
BIIB vs HAL Comparison
Compare BIIB & HAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HAL
- Stock Information
- Founded
- BIIB 1978
- HAL 1919
- Country
- BIIB United States
- HAL United States
- Employees
- BIIB N/A
- HAL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HAL Oilfield Services/Equipment
- Sector
- BIIB Health Care
- HAL Energy
- Exchange
- BIIB Nasdaq
- HAL Nasdaq
- Market Cap
- BIIB 25.1B
- HAL 28.0B
- IPO Year
- BIIB 1991
- HAL N/A
- Fundamental
- Price
- BIIB $156.46
- HAL $29.07
- Analyst Decision
- BIIB Buy
- HAL Strong Buy
- Analyst Count
- BIIB 26
- HAL 18
- Target Price
- BIIB $255.29
- HAL $40.50
- AVG Volume (30 Days)
- BIIB 1.5M
- HAL 9.1M
- Earning Date
- BIIB 10-30-2024
- HAL 01-22-2025
- Dividend Yield
- BIIB N/A
- HAL 2.34%
- EPS Growth
- BIIB 10.05
- HAL N/A
- EPS
- BIIB 11.06
- HAL 2.86
- Revenue
- BIIB $9,607,500,000.00
- HAL $23,073,000,000.00
- Revenue This Year
- BIIB N/A
- HAL $0.97
- Revenue Next Year
- BIIB N/A
- HAL $1.75
- P/E Ratio
- BIIB $14.14
- HAL $10.17
- Revenue Growth
- BIIB N/A
- HAL 0.93
- 52 Week Low
- BIIB $153.62
- HAL $27.26
- 52 Week High
- BIIB $268.30
- HAL $41.56
- Technical
- Relative Strength Index (RSI)
- BIIB 31.68
- HAL 39.20
- Support Level
- BIIB $158.44
- HAL $31.25
- Resistance Level
- BIIB $162.62
- HAL $32.56
- Average True Range (ATR)
- BIIB 3.35
- HAL 0.84
- MACD
- BIIB 0.74
- HAL -0.33
- Stochastic Oscillator
- BIIB 24.34
- HAL 9.33
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HAL Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the largest pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the past two decades.